Navigation Links
Scott & White Healthcare clinical trials target lymphoma, leukemia
Date:5/5/2010

Scott & White's Cancer Research Institute (CRI) is participating in an international study that targets adult relapsed or refractory B-cell Non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

"This study is important in our efforts to find new and better ways to treat patients with leukemia or lymphoma," said Arthur E. Frankel, M.D., director of Scott & White's Cancer Research Institute, and principal investigator for the Temple portion of the study. "Scott & White, as well as the entire Central Texas community, are fortunate to be included in this international research."

The Phase I/II study is open to eligible patients with previously treated B-cell non-Hodgkin's lymphoma (NHL), B-cell chronic lymphocytic leukemia (CLL), to include small lymphocytic lymphoma (SLL). B-cell lymphomas account for 80-90% of all Non-Hodgkin's Lymphomas. The clinical trial will evaluate the safety, tolerability, and efficacy of an investigative therapeutic research agent called CAT-8015.

This research will ultimately include 30 sites in the U.S., Canada and Europe and from 110 to 140 subjects. The study will last about 30 months.

"We want to determine if this agent is effective in destroying cancer cells using varying doses," said Dr. Frankel.

Descriptions:

  • Chronic lymphocytic leukemia (CLL), more common in people age 60 and older, is a B-cell disorder in which white blood cells live longer than normal and accumulate in the blood and bone marrow and sometimes the lymph nodes. This accumulation of white blood cells crowds out healthy lymphocytes and causes immune system problems. About 15,490 new cases of CLL were diagnosed in 2009.
  • CLL and Small Lymphocytic Lymphoma (SLL) are the same disease with slight variations. When the cancer cells are primarily in the lymph nodes, it's called SLL.
  • Follicular Lymphoma, a slow-growing Lymphoma, accounts for 20-30% of the cases of Non-Hodgkin's Lymphoma. It occurs equally among males and female adults over the age of 60.
  • Diffuse Large B-Cell Lymphoma is an aggressive Non-Hodgkin's Lymphoma (NHL) that occurs in B-cells, and accounts for two out of five cases of NHL.
  • Mantle cell lymphoma (MCL) accounts for about 1 in 20 Non-Hodgkin's Lymphoma diagnoses in the United States; and typically occurs in patients over 30 years old, most frequently in males over the age of 50.


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Related medicine news :

1. Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages
2. New Varicose Vein Treatment Center Opens in Prescott, Arizona
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. Allergy Relief, Chiropractic and Biofeedback Provided at New Absolute Health Clinic in Scottsdale, Arizona
5. SUNZ Insurance Company Selects Scott Robertson as President
6. James Scott Farrin Supports Radiothon for Duke Children's Hospital
7. Scott & White Healthcare pathologist is co-investigator on breast cancer study
8. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
9. Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period
10. Scott Roeder Trial: Randall Terry, Operation Rescue Founder and Insurrecta Nex Members to Attend Trial in Wichita
11. New study shows TGen spin-off boosts Scottsdale economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... ... All-Star Insurance, a family managed agency that offers insurance management assistance and personal ... of a new charity drive to benefit women in the area diagnosed with breast ... estimated 252, 710 new cases of invasive or high risk breast cancer will be ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... 2017 , ... Despite its pervasiveness, many physicians are unfamiliar with how best ... with clinical practice. Now, however, a timely review has been published in the ... etiology of NeuP and educating preclinical scientists on its diagnosis and choice of treatment. ...
(Date:6/22/2017)... ... June 23, 2017 , ... Rise Against Hunger ... June 21, 2017, at the Emeryville Center of Community Life. More than 374 ... world. , Rise Against Hunger (formerly Stop Hunger Now) meal packaging events are ...
(Date:6/20/2017)... , ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud ... on Wednesday, June 21. , “Introducing our product on QVC is something we all ... promote our travel pillow to more than 90 million homes in the United States,” said ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Iowa , June 6, 2017  Diplomat Specialty Infusion Group, ... sterile compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard ... controlled environment with a low level of pollutants. ... more IV nutrition consumers and better serve our Iowa ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
Breaking Medicine Technology: